argenx and Halozyme Announce License Agreement

argenx gains use of Halozyme’s ENHANZE drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx products

argenx and Halozyme Therapeutics, Inc. have entered a global collaboration and license agreement that enables use by argenx of Halozyme’s ENHANZE drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates.    The agreement provides argenx exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx’s lead asset efgartigimod (ARGX-113) and up to two additional targets, poten...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters